0JZ Stock Chart & Stats
€3.06
-€0.04(-2.55%)
At close: 4:00 PM EST
€3.06
-€0.04(-2.55%)
Day’s Range― - ―
52-Week Range€1.28 - €7.20
Previous CloseN/A
Volume0.00
Average Volume (3M)1.00
Market Cap
€354.83M
Enterprise Value€164.42M
Total Cash (Recent Filing)€1.76M
Total Debt (Recent Filing)€24.04M
Price to Earnings (P/E)―
Beta0.03
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.64
Shares Outstanding62,275,177
10 Day Avg. Volume0
30 Day Avg. Volume1
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)12.26
Price to Sales (P/S)0.00
P/FCF Ratio-5.81
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.46
Revenue Forecast (FY)€2.04M
Bulls Say, Bears Say
Bulls Say
Diversified Product PipelineA pipeline spanning structural heart and urology gives Affluent Medical multiple potential development paths rather than reliance on one indication. If candidates progress through clinical and regulatory stages, this breadth could support future commercialization opportunities and reduce concentration in a single product.
Prior Revenue ScalingThe earlier increase in revenue indicates that the company had demonstrated some ability to move beyond a purely pre-commercial stage before the 2025 setback. That history may provide a foundation for rebuilding commercial activity if its development programs advance and approvals or partnerships are achieved.
Substantial Asset BaseA substantial asset base provides an existing financial and operating foundation for continuing development activities. While leverage and equity erosion weaken flexibility, the asset base may still support execution of the pipeline and preserve resources for advancing products toward regulatory and commercial milestones.
Bears Say
Zero Reported RevenueZero reported annual revenue highlights the company’s limited commercial maturity and makes near-term operating self-sufficiency difficult to establish. The sharp reversal from prior low-base growth also raises uncertainty about commercialization progress and the durability of any future revenue recovery.
Persistent Cash BurnPersistent and worsening cash burn means the business consumes funding while advancing its products and has not yet converted development activity into internally generated cash. Continued negative free cash flow can restrict investment capacity and increase reliance on external financing over the coming quarters.
Rising LeverageHigher debt combined with sharply reduced equity materially weakens financial resilience and balance-sheet flexibility. The resulting leverage can limit management’s ability to fund clinical development, absorb setbacks, or negotiate from strength when additional financing is required.
Affluent Medical SA News
0JZ FAQ
What was Affluent Medical SA’s price range in the past 12 months?
Affluent Medical SA lowest stock price was €1.28 and its highest was €7.20 in the past 12 months.
What is Affluent Medical SA’s market cap?
Affluent Medical SA’s market cap is €354.83M.
When is Affluent Medical SA’s upcoming earnings report date?
Affluent Medical SA’s upcoming earnings report date is Sep 24, 2026 which is in 4 days.
How were Affluent Medical SA’s earnings last quarter?
Affluent Medical SA released its earnings results on Sep 25, 2025. The company reported -€0.238 earnings per share for the quarter.
Is Affluent Medical SA overvalued?
According to Wall Street analysts Affluent Medical SA’s price is currently Overvalued.
Does Affluent Medical SA pay dividends?
Affluent Medical SA does not currently pay dividends.
What is Affluent Medical SA’s EPS estimate?
Affluent Medical SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Affluent Medical SA have?
Affluent Medical SA has 62,275,177 shares outstanding.
What happened to Affluent Medical SA’s price movement after its last earnings report?
Affluent Medical SA reported an EPS of -€0.238 in its last earnings report. Following the earnings report the stock price went down -2.318%.
Which hedge fund is a major shareholder of Affluent Medical SA?
Currently, no hedge funds are holding shares in DE:0JZ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Affluent Medical SA
Carvolix S.A. operates as a medical technology firm, concurrently involved in both commercialization and clinical development, specializing in treatment solutions for structural heart ailments and cerebral strokes. The company's innovative endeavors encompass the creation of AI- and imaging-driven mini-robots, engineered for executing intricate medical procedures, as well as the development of biomimetic heart valves. Established on January 30, 2026, Carvolix S.A. maintains its headquarters in Aix-en-Provence, France.
Technical Analysis
MAUNA KEA TECHNOLOGIES
―
Theraclion SA
―
Diagnostic Medical Systems
―
Median Technologies
―
Implanet SA
―